China's deliberate concentration of anti cancer drugs at the provincial level has led to a marked decline in prices.

China's deliberate concentration of anti cancer drugs at the provincial level has led to a marked decline in prices.

Original title: China's anticancer drugs special provincial centralized procurement to achieve a marked decline in prices

"Economic reference daily" reporter learned that China's brewing will be the province as a unit, to carry out special centralized procurement of anti-cancer drugs. The purpose is to optimize the structure of clinical medication through centralized procurement with quantity, and to achieve a significant reduction in the terminal sales price of anticancer drugs on the basis of the state's anti cancer drug tax reduction.

An industry insider revealed that the national medical insurance bureau held a conference on centralized procurement of drugs in Shanghai, one of which was to give advice on the provincial special procurement of anti-cancer drugs in the next medical insurance catalogue.

"Implementing the special centralized procurement of major disease drugs, focusing on anticancer drugs, is to optimize the structure of clinical medication, reduce the cost of drug use, and further realize the effect of reducing the price on the basis of tax reduction to meet the needs of the masses." The people said.

It is understood that the scope of special centralized procurement of anticancer drugs basically covers the anticancer drugs within the scope of tax reduction. In addition, all localities can appropriately expand their scope according to factors such as drug usage, usage sum and clinical needs.

The phenomenon of "lowering taxes and not reducing prices" will end. People in the industry said that the products in the list of tax cuts that had been published earlier will be a special type of centralized procurement, which means that the remaining varieties will be the focus of the negotiations, in addition to the previously negotiated varieties of drug prices.

The state health insurance bureau has revealed that the National Medical Insurance Bureau will carry out access negotiations and incorporate more anti-cancer drugs into the catalogue after negotiating a reasonable price with the enterprise.

Ceng Yixin, deputy director of the National Health Committee, told a news conference in April 28th that after the formal implementation of the zero tariffs on imported drugs in May 1st, China will start the negotiations on the national centralized procurement of anti-cancer drugs and medical insurance access: the varieties of anti cancer drugs which have been included in the basic medical insurance drugs are to be carried out by more than 3 enterprises. Special and centralized bidding; the 3 varieties of production enterprises are encouraged to form a unified national purchase price through various ways such as negotiation and matching, and to organize experts to review and carry out access negotiations for the anti cancer drugs that have not been included in medical insurance reimbursement, and bring the eligible drugs into the scope of medical insurance drugs.

In response, there are reports that a number of multinational pharmaceutical companies have recently received an invitation to discuss prices with relevant departments. Insiders admit that this will be a tense and intense negotiation.

Li Ling, director of the health development research center of Peking University, said in an interview with the economic reference newspaper that strengthening the collection and reducing the price of drugs has entered a further step. She pointed out that, in response to the correct understanding of the drug market, the drug market can not reduce the price simply through competition. It is difficult for a hospital to negotiate with the needs of a hospital. It is difficult to create pressure on the drug production side. Only by making full use of the advantages of the big market in China to change the price, we can truly achieve the effect we want.

According to statistics, China is the second largest pharmaceutical market in the world after sales, and is a key growth market for cancer treatment drugs. Specifically, IMS's 2017 global tumor trend report showed that the global cost of cancer treatment and maintenance therapy in 2016 accounted for 10.3% of global drug sales, and an average annual growth of close to 9% in five years. At the same time, the related data issued by the forward industry research institute showed that the sales scale of antitumor drugs in China has maintained an average annual growth rate of around 20%. In 2017, it is about 141 billion yuan. It is expected that there will be a significant "price change" effect, but the growth rate will remain between 15% and 17%.

In fact, the national negotiations have brought about a substantial drop in the price of some drugs. Since 2016, the relevant state departments have organized the national drug price negotiation pilot and the national medical insurance catalogue for some patent and exclusive drugs. The first, second batch of negotiated catalogues have 39 negotiated varieties with an average price of more than 50%, and all have been included in the national medical insurance catalogue. Up to now, compared with the average retail price in 2016, the average decline in negotiated drugs reached 44%, up to 70%, and the payment standards after most of the import of imported drugs were lower than those in the surrounding international market.

It is worth noting that, in the future, the purchase of anti-cancer drugs may be included in the same competitive bidding group through the quality conformance evaluation of the generic drugs and the original research drugs, and bid for the purchase according to the same rules.

"We encourage medical institutions and staff to use drugs that are much more expensive. In the case of manufacturers and drugs that have no justification or abuse of market dominance that refuses to reduce prices, the scope of clinical use is further stricter, and alternative drugs and therapies are encouraged and encouraged. " The people said.

Li Ling said that, as the most populous country, and the largest country in the pharmaceutical market, the government should take a tough fight to further reduce the price of pharmaceutical companies. It is hard to touch the nerve of monopolist, and the negotiation of natural price is hard to achieve. If there are rewards and penalties, who will cut prices and who will benefit will also bring some impetus to the price reduction of pharmaceutical enterprises. "

But Li Ling also pointed out that, because the drug security system is a system arrangement, reducing drug prices not only need to work on drug procurement and procurement, but also to further increase support for related industries, and encourage domestic original research and generic drugs.

Reporter Liang Qian Chen Hongyi reports from Fuzhou, Beijing

Source: economic reference

Editor in responsibility: Zhang Yiling

Waonews is a news media from China, with hundreds of translations, rolling updates China News, hoping to get the likes of foreign netizens